Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2013

Open Access 01-12-2013 | Research article

Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial

Published in: BMC Medicine | Issue 1/2013

Login to get access

Abstract

Background

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic myelopathy characterized by motor dysfunction of the lower extremities and urinary disturbance. Immunomodulatory treatments are the main strategy for HAM/TSP, but several issues are associated with long-term treatment. We conducted a clinical trial with prosultiamine (which has apoptotic activity against HTLV-I-infected cells) as a novel therapy in HAM/TSP patients.

Methods

We enrolled 24 HAM/TSP patients in this open-label clinical trial. Prosultiamine (300 mg, orally) was administered once daily for 12 weeks. We monitored changes in the motor function of the lower extremities and urinary function as well as copy numbers of the HTLV-I provirus in peripheral blood mononuclear cells (PBMCs).

Results

Improvement in the motor function of the lower extremities based on a reduction in spasticity (for example, decrease in time required for walking and descending a flight of stairs) was observed. In an urodynamic study (UDS), bladder capacity and detrusor pressure and then maximum flow rate increased significantly. Detrusor overactivity and detrusor-sphincter dyssynergia improved in 68.8% and 45.5% of patients observed at pretreatment, respectively. Improvement in UDS corresponded with improvements in the score of nocturia-quality of life questionnaire. HTLV-I proviral copy numbers in PBMCs decreased significantly (approximately 15.4%) compared with pretreatment levels.

Conclusions

These data suggest that prosultiamine can safely improve motor dysfunction of the lower extremities and urinary disturbance as well as reduce HTLV-I provirus levels in peripheral blood. It therefore has potential as a new therapeutic tool for HAM/TSP patients.

Trial registration

University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number, UMIN000005969.
Please see related commentary: http://​www.​biomedcentral.​com/​1741-7015/​11/​183.
Appendix
Available only for authorised users
Literature
1.
De-Thé G, Bomford R: An HTLV-I vaccine: why, how, for whom?. AIDS Res Hum Retroviruses. 1993, 9: 381-386.CrossRefPubMed
2.
Hollsberg P, Hafler DA: Pathogenesis of diseases induced by human T-lymphotropic virus type I infection. N Engl J Med. 1993, 328: 1173-1182.CrossRefPubMed
3.
Yoshida M: Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001, 19: 475-496.CrossRefPubMed
4.
Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M: HTLV-I associated myelopathy, a new entity. Lancet. 1986, 8488: 1031-1032.CrossRef
5.
Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A: Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol. 1987, 21: 117-122.CrossRefPubMed
6.
Nakamura T, Nishiura Y, Eguchi K: Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cent Nerv Syst Agents Med Chem. 2009, 9: 137-149.CrossRefPubMed
7.
Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K: Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a 2 year follow-up study after corticosteroid therapy. J Neurol Sci. 1991, 106: 41-49.CrossRefPubMed
8.
Nakamura T: HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol. 2009, 47: 182-194.PubMed
9.
Fujiwara M, Watanabe H, Matsui K: “Allithiamine” a newly found derivative of vitamine B1. I. discovery of allithiamine. J Biochem (Tokyo). 1954, 41: 29-39.
10.
Matsukawa T, Yurugi S: On the structure of allithiamine. Proc Japan Acad. 1952, 28: 146-149.
11.
Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K: Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther. 2009, 14: 533-542.PubMed
12.
Osame M: Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. Human Retrovirology: HTLV. Edited by: Blattner WA. 1990, New York, NY: Raven, 191-197.
13.
Osame M, Igata A, Matsumoto M: HTLV-I-associated myelopathy (HAM) revisited. HTLV-I and the Nervous System. Edited by: Román GC, Vernant J-C, Osame M. 1989, New York, NY: Alan R, Liss, Inc, 213-223.
14.
Bohannon RW, Smith MB: Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987, 67: 206-207.PubMed
15.
Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, MacDonaqh RP, Noble JG: Development and validation of a quality-of-life measure for men with nocturia. Urology. 2004, 63: 481-486.CrossRefPubMed
16.
Yu HJ, Chen FY, Huang PC, Chen THH, Chie WC, Liu CY: Impact of nocturia on symptom-specific quality of life among community-dwelling adults aged 40 years and older. Urology. 2006, 67: 713-718.CrossRefPubMed
17.
Yoshida M, Ikeda S: Development of the Japanese version of the nocturia quality of life questionnaire (N-QOL) [in Japanese]. Jpn J Urol Surg. 2010, 23: 833-838.
18.
Veldhuyzen Van Zanten SJO, Chiba N, Armstrong D, Barkun AN, Thomson ABR, Mann V, Escobedo S, Chakraborty B, Nevin K: Validation of a 7-point global overall symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006, 23: 521-529.CrossRefPubMed
19.
Oliveira P, Castro NM, Carvalho EM: Urinary and sexual manifestations of patients infected by HTLV-1. Clinics. 2007, 62: 191-196.CrossRefPubMed
20.
Castro NM, Rodrigues W, Freitas DM, Muniz A, Oliveira P, Carvalho EM: Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology. 2007, 69: 813-818.CrossRefPubMed
21.
Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CRM, Weber JN: Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomized trial. Retrovirology. 2006, 3: 63.CrossRefPubMedPubMedCentral
22.
Olindo S, Belrose G, Gillet N, Rodriguez S, Boxus M, Verlaeten O, Asquith B, Bangham C, Signaté A, Smadja D, Lezin A, Césaire R, Willems L: Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood. 2011, 118: 6306-6309.CrossRefPubMed
Metadata
Title
Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial
Publication date
01-12-2013
Published in
BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-11-182

Other articles of this Issue 1/2013

BMC Medicine 1/2013 Go to the issue

Research article

A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model

Correspondence

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

Research article

Effectiveness of Primary Care Triple P on child psychosocial problems in preventive child healthcare: a randomized controlled trial

Research article

Characteristics, changes and influence of body composition during a 4486 km transcontinental ultramarathon: results from the Transeurope Footrace mobile whole body MRI-project

Research article

Promoting networks between evidence-based medicine and values-based medicine in continuing medical education

Research article

Neuromuscular electrical stimulation for preventing skeletal-muscle weakness and wasting in critically ill patients: a systematic review